Hydroxychloroquine May be Beneficial for Preeclampsia

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

462 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-01-01

Study Completion Date

2026-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this research is to investigate the impact of hydroxychloroquine on the incidence of hypertensive pregnancy disorders in women with a history of recurrent spontaneous abortion (RSA).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of Hydroxychloroquine Sulfate in the Treatment of Recurrent Spontaneous Abortion With Antiphospholipid Syndrome

NCT04624269

Antiphospholipid Syndrome Recurrent Miscarriage

UNKNOWN PHASE4

Hydroxychloroquine and Unexplained Recurrent Miscarriage

NCT04228263

Unexplained Recurrent Miscarriage

COMPLETED NA

HYDROxychloroquine in Syndrome Primary AntiPhospholipid

NCT04275778

Antiphospholipid Syndrome in Pregnancy Anticoagulants

UNKNOWN PHASE2

Hydroxychloroquine for Prevention of Recurrent Miscarriage.

NCT03165136

Recurrent Miscarriage First Trimester Abortion

ACTIVE_NOT_RECRUITING PHASE3

Hydroxychloroquine in Prevention of Preeclampsia

NCT04755322

Preeclampsia

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Preeclampsia affects about 3-5% of all pregnancies and is estimated to cause at least 42 000 maternal deaths annually, remaining an important cause of death and complications for the mother and baby. However, no treatment yet has been found that affects disease progression except for termination of pregnancy which may cause iatrogenic preterm labor. Therefore, keenly sought for approaches to improving clinical outcomes in pre-eclampsia would be needed.

Hydroxychloroquine (HCQ), an antimalarial drug, is commonly used in the treatment of pregnant women with RSA and has proven to be safe for both the mother and the fetus. Because of the antioxidant effect, anti-inflammatory effect, and vasculoprotective effect of HCQ, it has been thought to be beneficial in the prevention of preeclampsia.

Therefore, we conducted a retrospective cohort study to evaluate the impact of HCQ treatment on the prevention of preeclampsia in RSA pregnancies.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pre-Eclampsia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Hydroxychloroquine treatment group

The Hydroxychloroquine treatment group was defined as having exposure to Hydroxychloroquine during pregnancy.

Hydroxychloroquine

Intervention Type DRUG

Hydroxychloroquine was administered during pregnancy

Hydroxychloroquine nontreatment group

The Hydroxychloroquine nontreatment group was defined as having no exposure to Hydroxychloroquine during pregnancy.

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Hydroxychloroquine

Hydroxychloroquine was administered during pregnancy

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Plaquenil

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. singleton pregnant women
2. with a history of two or more miscarriages

Exclusion Criteria

1. indication to a treatment according to the severe cardiovascular, immune, respiratory, gastrointestinal/liver and biliary system, kidney and urinary system, nervous system, musculoskeletal system, psychiatric, infectious disease, malignancy,
2. major malformation of the fetus diagnosed at 11-13 weeks of gestation.
3. Known paternal, maternal, or embryo chromosome abnormality;
4. Abnormal uterine anatomy at hysterosalpingography/hysteroscopy or hydrosonography that might explain RM in the first trimester of pregnancy;
5. Maternal endocrine dysfunction: premature ovarian failure, hyperprolactinemia, corpus luteal insufficiency, untreated diabetes mellitus or untreated thyroid dysfunction.

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No